[Adjuvant concurrent chemoradiotherapy for resected locally advanced lung cancer outpatients].
Recently, adjuvant chemoradiotherapy showed possible survival advantage in the western prospective studies. A feasibility study was conducted. Adjuvant concurrent chemoradiotherapy with carboplatin (CBDCA) + paclitaxel (PTX) was performed to 4 outpatients with resected locally advanced lung cancer. A total of 60 Gy was given during about 7 weeks, and concurrent CBDCA 2 mg/AUC + PTX 45 mg/m2 was administered weekly. Grade 2 neutropenia was seen in 2 patients, grade 2 esophagitis was seen in 1, and grade 2 peripheral neuritis was in 1. Grade 3 or more toxicity was never seen. One patient had to be hospitalized because of esophagitis, but other 3 patients had completed all course of the therapy as outpatients. Adjuvant concurrent chemoradiotherapy with CBDCA + PTX was thought to be feasible to the resected locally advanced lung cancer patients. Prospective study will be conducted to examine the efficacy of this treatment.
Endo
Chiaki
C
Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Kondo
T
T
D000368:Aged; D000553:Ambulatory Care; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011013:Pneumonectomy; D018714:Radiotherapy, Adjuvant
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel